CN1300315C - 奶牛之犊牛前胸腺素基因及其克隆方法与应用 - Google Patents
奶牛之犊牛前胸腺素基因及其克隆方法与应用 Download PDFInfo
- Publication number
- CN1300315C CN1300315C CNB2004100357369A CN200410035736A CN1300315C CN 1300315 C CN1300315 C CN 1300315C CN B2004100357369 A CNB2004100357369 A CN B2004100357369A CN 200410035736 A CN200410035736 A CN 200410035736A CN 1300315 C CN1300315 C CN 1300315C
- Authority
- CN
- China
- Prior art keywords
- glu
- prothymosin
- asp
- gene
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 68
- 241000283690 Bos taurus Species 0.000 title claims abstract description 36
- 244000309466 calf Species 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 23
- 238000010367 cloning Methods 0.000 title claims abstract description 10
- 235000013336 milk Nutrition 0.000 title claims 7
- 239000008267 milk Substances 0.000 title claims 7
- 210000004080 milk Anatomy 0.000 title claims 7
- 210000004907 gland Anatomy 0.000 title 1
- 229940088597 hormone Drugs 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 239000013604 expression vector Substances 0.000 claims abstract description 15
- 108010046075 Thymosin Proteins 0.000 claims description 26
- 102000007501 Thymosin Human genes 0.000 claims description 24
- 230000002441 reversible effect Effects 0.000 claims description 22
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims description 22
- 239000002299 complementary DNA Substances 0.000 claims description 19
- 239000013612 plasmid Substances 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- 238000013461 design Methods 0.000 claims description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 5
- 150000001413 amino acids Chemical group 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 102220369447 c.1352G>A Human genes 0.000 claims 2
- 230000004087 circulation Effects 0.000 claims 2
- 230000001186 cumulative effect Effects 0.000 claims 2
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 238000009395 breeding Methods 0.000 claims 1
- 230000001488 breeding effect Effects 0.000 claims 1
- 102220369445 c.668T>C Human genes 0.000 claims 1
- 102220023258 rs387907548 Human genes 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 230000002992 thymic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 102000004169 proteins and genes Human genes 0.000 abstract description 15
- 210000001541 thymus gland Anatomy 0.000 abstract description 13
- 235000013365 dairy product Nutrition 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 238000010839 reverse transcription Methods 0.000 abstract description 6
- 238000012408 PCR amplification Methods 0.000 abstract description 5
- 238000004113 cell culture Methods 0.000 abstract description 3
- 238000003757 reverse transcription PCR Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 17
- 210000004698 lymphocyte Anatomy 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 108010014750 prothymosin alpha Proteins 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 108010078233 Thymalfasin Proteins 0.000 description 5
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 5
- 229960004231 thymalfasin Drugs 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 4
- 108010038633 aspartylglutamate Proteins 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 3
- 102100037925 Prothymosin alpha Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- HPKSHFSEXICTLI-CIUDSAMLSA-N Arg-Glu-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HPKSHFSEXICTLI-CIUDSAMLSA-N 0.000 description 2
- BZMWJLLUAKSIMH-FXQIFTODSA-N Asn-Glu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BZMWJLLUAKSIMH-FXQIFTODSA-N 0.000 description 2
- OPEPUCYIGFEGSW-WDSKDSINSA-N Asn-Gly-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OPEPUCYIGFEGSW-WDSKDSINSA-N 0.000 description 2
- ZELQAFZSJOBEQS-ACZMJKKPSA-N Asp-Asn-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZELQAFZSJOBEQS-ACZMJKKPSA-N 0.000 description 2
- XAJRHVUUVUPFQL-ACZMJKKPSA-N Asp-Glu-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XAJRHVUUVUPFQL-ACZMJKKPSA-N 0.000 description 2
- CJUKAWUWBZCTDQ-SRVKXCTJSA-N Asp-Leu-Lys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O CJUKAWUWBZCTDQ-SRVKXCTJSA-N 0.000 description 2
- CTWCFPWFIGRAEP-CIUDSAMLSA-N Asp-Lys-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O CTWCFPWFIGRAEP-CIUDSAMLSA-N 0.000 description 2
- WAEDSQFVZJUHLI-BYULHYEWSA-N Asp-Val-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WAEDSQFVZJUHLI-BYULHYEWSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- MCAVASRGVBVPMX-FXQIFTODSA-N Gln-Glu-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MCAVASRGVBVPMX-FXQIFTODSA-N 0.000 description 2
- CELXWPDNIGWCJN-WDCWCFNPSA-N Gln-Lys-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CELXWPDNIGWCJN-WDCWCFNPSA-N 0.000 description 2
- RUFHOVYUYSNDNY-ACZMJKKPSA-N Glu-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O RUFHOVYUYSNDNY-ACZMJKKPSA-N 0.000 description 2
- NTBDVNJIWCKURJ-ACZMJKKPSA-N Glu-Asp-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NTBDVNJIWCKURJ-ACZMJKKPSA-N 0.000 description 2
- JPHYJQHPILOKHC-ACZMJKKPSA-N Glu-Asp-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JPHYJQHPILOKHC-ACZMJKKPSA-N 0.000 description 2
- DSPQRJXOIXHOHK-WDSKDSINSA-N Glu-Asp-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O DSPQRJXOIXHOHK-WDSKDSINSA-N 0.000 description 2
- CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 description 2
- MTAOBYXRYJZRGQ-WDSKDSINSA-N Glu-Gly-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MTAOBYXRYJZRGQ-WDSKDSINSA-N 0.000 description 2
- OAGVHWYIBZMWLA-YFKPBYRVSA-N Glu-Gly-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)NCC(O)=O OAGVHWYIBZMWLA-YFKPBYRVSA-N 0.000 description 2
- HRBYTAIBKPNZKQ-AVGNSLFASA-N Glu-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O HRBYTAIBKPNZKQ-AVGNSLFASA-N 0.000 description 2
- UXJHNZODTMHWRD-WHFBIAKZSA-N Gly-Asn-Ala Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O UXJHNZODTMHWRD-WHFBIAKZSA-N 0.000 description 2
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- RDLSEGZJMYGFNS-FXQIFTODSA-N Met-Ser-Asp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RDLSEGZJMYGFNS-FXQIFTODSA-N 0.000 description 2
- DBALDZKOTNSBFM-FXQIFTODSA-N Pro-Ala-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O DBALDZKOTNSBFM-FXQIFTODSA-N 0.000 description 2
- 239000006004 Quartz sand Substances 0.000 description 2
- GYDFRTRSSXOZCR-ACZMJKKPSA-N Ser-Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GYDFRTRSSXOZCR-ACZMJKKPSA-N 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- MPUMPERGHHJGRP-WEDXCCLWSA-N Thr-Gly-Lys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N)O MPUMPERGHHJGRP-WEDXCCLWSA-N 0.000 description 2
- MGJLBZFUXUGMML-VOAKCMCISA-N Thr-Lys-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MGJLBZFUXUGMML-VOAKCMCISA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- CGGVNFJRZJUVAE-BYULHYEWSA-N Val-Asp-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CGGVNFJRZJUVAE-BYULHYEWSA-N 0.000 description 2
- VLOYGOZDPGYWFO-LAEOZQHASA-N Val-Asp-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VLOYGOZDPGYWFO-LAEOZQHASA-N 0.000 description 2
- 108010087924 alanylproline Proteins 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 2
- 108010072405 glycyl-aspartyl-glycine Proteins 0.000 description 2
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 2
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 2
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108010027845 thymosin alpha(1) (24-28) Proteins 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000048470 Dixin Human genes 0.000 description 1
- 108700037673 Dixin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- CKRUHITYRFNUKW-WDSKDSINSA-N Glu-Asn-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O CKRUHITYRFNUKW-WDSKDSINSA-N 0.000 description 1
- SOYWRINXUSUWEQ-DLOVCJGASA-N Glu-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O SOYWRINXUSUWEQ-DLOVCJGASA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 101000717237 Tobacco streak virus (strain WC) RNA-directed RNA polymerase 2a Proteins 0.000 description 1
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- -1 acts on T cells Chemical compound 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 101150087698 alpha gene Proteins 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
奶牛之犊牛前胸腺素基因及其克隆方法与应用,属于分子生物学和生物技术领域。本发明从奶牛胸腺组织中分离出编码奶牛前胸腺素的基因。设计了反转录和PCR扩增的特异性引物对,利用反转录-聚合酶链式反应,从奶牛中分离出编码前胸腺素的基因,基因序列长度330个碱基,进一步构建表达载体,转化宿主细胞。在该宿主细胞培养液中获得前胸腺素蛋白,获得的前胸腺素蛋白具有较高的活性。本发明的重组基因可用于医药产品-胸腺素的工业化生产。
Description
(一)技术领域
本发明涉及从奶牛胸腺组织中分离前胸腺素α基因及其克隆、重组及表达方法和表达产物的应用,属于分子生物学和生物技术领域。
(二)背景技术
胸腺是机体免疫系统的中枢器官,它所分泌的胸腺素是一组活性肽类物质,分为α和β族胸腺素。在疾病治疗中以α族胸腺素为主。胸腺素主要作用于T细胞,促进T细胞的分化和成熟,调节B细胞抗体产生水平,维持机体免疫系统的平衡,提高杀伤细胞和巨噬细胞活性、促进白细胞介素-2和α干扰素的合成等作用。前胸腺素α与胸腺素α1一样具有多种和近似相同的作用,如治疗系统性红斑狼疮、肿瘤、乙型和丙型肝炎、其他病毒性疾病、自身免疫性疾病和先天性免疫缺陷病等。胸腺素(胸腺肽)联合乙肝疫苗具有免疫调节和抗病毒作用。作者认为胸腺素乙肝疫苗的应用增强了患者肝细胞抗凋亡的能力,减轻肝细胞的坏死程度,从而改善了患者的免疫功能,增强了对HBV的抑制作用,减轻了肝细胞的免疫损伤,促进了肝细胞修复,改善了蛋白代谢。目前,世界上还没有研究出一种比较理想的抗病毒药物,因此对病毒病只能采取提高机体抵抗力和疫苗特异性接种预防的办法,多年的临床实践证实胸腺素对病毒病均有一定的治疗和预防作用,也是目前与干扰素配伍使用的抗病毒治疗药物之一,它们在乙肝、丙肝和肿瘤的治疗中发挥了巨大的作用。
目前,国外主要采用化学合成法生产胸腺素α1。意大利Sciclone公司研制的合成胸腺素α1已投放市场,国内胸腺素α1仍没有形成产业化生产。市场出售的胸腺素α1均为人工合成,成本高。组织提取又受到材料来源的限制,且产量很低、价格比较昂贵,应用受到限制。
(三)发明内容
本发明针对现有技术的不足,提供一种奶牛的犊牛前胸腺素基因及其克隆方法和应用。本发明首次从奶牛中分离出编码奶牛前胸腺素的全长cDNA,连接到表达载体上,再转化酵母菌株,表达产物具有较高的活性。
奶牛之犊牛前胸腺素基因,具有如下序列:
1.SEQ ID NO.1:DNA序列
(1)序列特征
*长度:330个碱基对
*类型:核酸
*链型:双链
*拓扑结构:线性
(2)分子类型:cDNA
(3)最初来源:奶牛胸腺组织
(4)序列描述:
ATGTCAGACG CGGCCGTGGA CAACAGCTCC GAGATCACCA CCAAGGACTT 50
AAAGGAGAAG AAGGAAGTTG TGGAGGAGGC GGAGAATGGG AGAGAGGCAC 100
CTGCAAATGG GAATGCTAAT GAGGAAAATG GGGAGCAGGA AGCAGACAAC 150
GAGGTAGACG AAGAAGAGGA GGAAGGTGGG GAGGAAGAGG AGGAGGAGGA 200
AGGTGACGGT GAGGAAGAGG ACGGAGATGA AGATGAGGAG GCCGAGGCAG 250
CTACGGGCAA ACGGGCAGCT GAAGATGACG AGGATAACGA TGTGGATACC 300
AAGAAGCAGA AGACTGATAA AGATGACTAG 330
2.SEQ ID NO.2:氨基酸序列
(1)序列特征
*长度:109氨基酸
*类型:氨基酸
*链型:单链
*拓扑结构:线型
(2)分子类型:蛋白质
(3)序列描述
Met Ser Asp Ala Ala Val Asp Asn Ser Ser Glu Ile Thr Thr Lys
1 5 10 15
Asp Leu Lys Glu Lys Lys Glu Val Val Glu Glu Ala Glu Asn Gly
20 25 30
Arg Glu Ala Pro Ala Asn Gly Asn Ala Asn Glu Glu Asn Gly Glu
35 40 45
Gln Glu Ala Asp Asn Glu Val Asp Glu Glu Glu Glu Glu Gly Gly
50 55 60
Glu Glu Glu Glu Glu Glu Glu Gly Asp Gly Glu Glu Glu Asp Gly
65 70 75
Asp Glu Asp Glu Glu Ala Glu Ala Ala Thr Gly Lys Arg Ala Ala
80 85 90
Glu Asp Asp Glu Asp Asn Asp Val Asp Thr Lys Lys Gln Lys Thr
95 100 105
Asp Lys Asp Asp 109。
本发明奶牛之犊牛前胸腺素基因的克隆方法如下,包括如下步骤:
(1)设计特异性引物:
正向引物1:CCA TCT TTG CAT TGT TCC
反向引物2:CTC ATA CAA ACC AAC TCA TTA TAG TAC AGC
(2)从奶牛的犊牛胸腺组织中提取总RNA或mRNA,然后用反转录酶和反向引物2由前胸腺素基因的mRNA来产生双链的mRNA/cDNA杂合分子;
(3)用DNA聚合酶、正向引物1和反向引物2在步骤(2)后通过PCR反应产生双链的cDNA分子;
(4)将所得的双链的cDNA分子插入载体内,转化宿主细胞;
(5)宿主细胞增殖后得到含有前胸腺素基因的质粒:
a)提取和确定质粒中前胸腺素基因,
b)将上述基因插入到表达载体内,构建重组表达载体,
c)上述重组表达载体转化宿主细胞,
d)上述宿主细胞在介质中培养繁殖后,累积前胸腺素蛋白。
上述步骤(5)表达累积的前胸腺素蛋白被分离和纯化,得到的是犊牛前胸腺素蛋白,该蛋白具有SEQ ID NO.2所示的氨基酸序列。
上述步骤(2)的反应组分如下:
反转录酶 1ul
反向引物 2ul
胸腺素基因的mRNA 13ul
5倍的RT-Buffer 5ul
10mM dNTP 1ul
上述步骤(3)的的反应组分和反应条件如下:
10倍反应缓冲液 5μl
25mM MgCl2 4μl
10mM dNTP 1μl
正向引物1 5p mol
反向引物2 5p mol
模板cDNA 2μl
DNA聚合酶 0.5μl
灭菌无离子水 36.5μl
总体积 50μl
PCR反应条件:
94℃4分钟;循环:94℃45秒,55℃50秒,72℃40秒,共30个循环,72℃延伸3分钟。
将PCR扩增产物纯化,连接到DNA载体上。将重组DNA载体转化感受态细胞。含有重组DNA载体的细胞在介质中培养增殖,筛选阳性培养物。将阳性培养物继续培养增殖后,提取质粒,进行电泳、酶切和PCR扩增鉴定,并进行序列测定。测序结果表明,本发明获得了一个330bp的DNA片段,经与基因库中的前胸腺素基因序列比较,证实该330bp的DNA片段为奶牛的犊牛前胸腺素基因。
本发明通过分离前胸腺素α基因,前胸腺素α基因的克隆、鉴定、序列测定;含有前胸腺素α基因的重组基因的构建;这种重组基因能在宿主细胞中累积表达前胸腺素蛋白;该重组基因被用于生产前胸腺素;基因技术表达的前胸腺素α蛋白具有天然产物的生物学活性。奶牛的犊牛前胸腺素α基因具有SEQ ID NO.1的特征,表达产生的奶牛前胸腺素α蛋白具有SEQ ID NO.2所示的特征。本发明的重组基因可用于医药产品-胸腺素的工业化生产。
本发明的前胸腺素基因序列长度330个碱基,比所公布的某些人和动物的前胸腺素基因缺失3个碱基。与人前胸腺素基因AF348514、BC003510、BC022433、BC051265、J04799和L21693的核苷酸差异率分别为9.8%,9.8%,10.5%,9.8%,10.6%,11.2%;与鸡BM486191前胸腺素基因的核苷酸差异率为18.5%,与鼠M20035和NM008972前胸腺素基因的核苷酸差异率为10.1%。
根据本发明获得的奶牛前胸腺素基因的核苷酸序列,设计下列引物,以构建表达载体。
正向引物1’:ATG TCA GAC GCG GCC GTG
反向引物2’:CTC GAG CTA GTC ATC TTT ATC AGT CTT C
以牛胸腺总RNA反转录的cDNA为模板,PCR扩增出含全长编码框的序列,用XhoI和EcoRI酶切PCR产物,将酶切片段连接到表达载体上。利用热激法转化原核宿主细胞,挑选阳性克隆,进行测序鉴定。
纯化的重组DNA载体酶切后线性化,用氯化铯法转化酵母细胞,在培养基介质中筛选抗性转化子。
在介质培养基中诱导前胸腺素的表达,每天取上清液1ml,诱导表达7天。样品经SDS-PAGE后,银染。根据标准蛋白确定表达产物的分子量为:1.3×104D。
前胸腺素的生物活性测定采用3H-TdR掺入法,取小鼠脾脏在钢筛上研磨后用淋巴细胞分离液分离出单核细胞,用PBS洗后,悬于含10%FCS的1640培养液中,向96孔培养板中加入4×105/孔的脾细胞和125ug/孔的ConA。在二氧化碳培养箱中于37℃培养6h,再加入不同浓度的融合蛋白和商品Tα1,继续培养72h,每孔加入3H-TdR185×10-3GBq继续培养6h,收获细胞于玻璃纤维滤纸上,晾干后用液闪记数仪检测cpm值,按下列公式计算增殖率:
增殖率(%)=(实验组cpm值-对照组cpm值)/对照组cpm值×100%
结果表明:前胸腺素对小鼠脾淋巴细胞具有明显的增殖效应。
本发明所获得的犊牛前胸腺素cDNA通过现有的基因工程技术方法,转入酵母菌并得以表达,可用来生产能提高人体免疫力,并具有抗癌作用的胸腺素,用于医药产品的生产制备。
本发明利用基因表达方法生产前胸腺素既解决了原料来源问题,也解决了工业化大量生产的瓶颈,同时可降低胸腺素现在的市场价格,开拓更广阔的应用范围。由于胸腺素蛋白在医学领域所起的作用,本发明从奶牛胸腺组织中分离出编码奶牛前胸腺素的基因,设计了反转录和PCR扩增的特异性引物对,利用反转录-聚合酶链式反应,从奶牛中分离出编码前胸腺素的基因。进一步构建表达载体,转化宿主细胞。在该宿主细胞培养液中获得前胸腺素蛋白,获得的前胸腺素蛋白具有较高的活性。
(四)附图说明
图1为前胸腺素基因编码区PCR电泳图谱,其中泳道1为100bp的标准DNA分子量Mark,泳道2和3为目的基因阳性PCR。
图2为编码区序列的质粒酶切图谱,其中泳道1为100bp的标准DNA分子量Mark,泳道2为1kb的标准DNA分子量Mark,泳道3-6为阳性质粒酶切结果。
图3为表达载体的酶切图谱,其中泳道1为1kb的标准DNA分子量Mark,泳道2为阴性对照,泳道3为阳性。从3切出的330bp大小的条带可以看出表达载体已经构建成功。
图4为前胸腺素的活性测定图即表达的前胸腺素对小鼠脾淋巴细胞增殖的影响图。其中横坐标为作用时间,纵坐标为小鼠脾淋巴细胞的增殖率。“—▲—”表示转基因工程菌表达物的增殖率,“—■—”表示商品前胸腺素的增殖率。以前胸腺素先与淋巴细胞保温5小时左右,再加入ConA刺激,产生的促增殖效应最佳。
(五)具体实施方式
下面结合具体实施例对本发明作进一步说明。
实施例1:
一、奶牛之犊牛胸腺组织的采集与处理
从一头12日龄的犊公牛体采集胸腺组织,冷冻保存于-80℃冰箱。这头犊公牛系黑白花奶牛品系。取-80℃冰箱保存的胸腺组织3克剪碎后,放置在一无菌乳钵中,加入无菌石英砂研磨,按1∶3比例加入0.01M灭菌磷酸盐缓冲液制成细胞悬液,于-20℃冰箱保存备用。
二、奶牛前胸腺素α基因反转录和PCR扩增的引物设计
由基因库下载了6个人、1个鸡和2个鼠的前胸腺素基因序列,登录编号分别为AF348514、BC003510、BC022433、BC051265、J04799、L21693和BM486191。用生物学软件比较分析了上述基因的序列差异或同源性,设计一对引物,这对引物在前胸腺素mRNA反转录和cDNA扩增获得前胸腺素α基因方面具有很重要的意义:
正向引物1:CCA TCT TTG CAT TGT TCC
反向引物2:CTC ATA CAA ACC AAC TCA TTA TAG TAC AGC
反向引物2被用于前胸腺素mRNA的反转录;正向引物1和反向引物2一起被用于前胸腺素α基因的PCR扩增。
三、奶牛前胸腺素α基因的克隆方法
1.总RNA的提取
a)将-20℃冰箱保存的犊牛胸腺细胞悬液反复冻融2次。
b)于450μl胸腺细胞悬液中加入450μl含有β-巯基乙醇的细胞裂解液和450μl无水乙醇。
c)用硅胶柱吸附核酸。
d)用缓冲液洗涤硅胶柱。
e)用无RNase酶的灭菌水洗脱核酸,离心收集于试管中。
f)向上述RNA提取物中加入RNase抑制剂。
2.mRNA反转录形成mRNA/cDNA杂合链(第一链):
首先设计下列引物:
正向引物1:CCA TCT TTG CAT TGT TCC
反向引物2:CTC ATA CAA ACC AAC TCA TTA TAG TAC AGC
取2ug总RNA,加入5倍RT缓冲液5μl,10mM的dNTP 1μl,反向引物21μl,反转录酶10u,42℃反应60分钟,72℃反应10分钟终止反应。
3.用PCR方法,以正向引物1、反向引物2和DNA聚合酶等合成犊牛前胸腺素基因的双链cDNA片段。
(1)反应体系
10倍反应缓冲液 5μl
25mM MgCl 24μl
10mM dNTP 1μl
正向引物1 5p mol
反向引物2 5p mol
模板cDNA 2μl
Taq DNA聚合酶 0.5μl
无菌水 36.5μl
总体积 50μl
(2)PCR反应条件
94℃4分钟;循环:94℃45秒,55℃50秒,72℃40秒,共30个循环,72℃延伸3分钟。
4.基因克隆:取2μl PCR产物与pGEM-T easy载体进行连接,具体操作步骤按照Promega公司产品pGEM-T easy Vector system说明书进行。然后连接产物转化大肠杆菌DH5a感受态菌株,在表面涂有5-溴-4-氯-3-吲哚-D-半乳糖苷和X-gal的含氨苄青霉素的LB平板上生长过夜,挑取白色单菌落,在LB液体培养基中摇菌培养过夜。
5.质粒DNA的提取:取过夜培养菌液1-2ml,10000rpm离心1分钟。收集细胞,用美国Promega公司的微量DNA纯化试剂盒纯化质粒,纯化步骤按说明书进行。
6.序列测定:取纯化的质粒用载体引物进行全自动测序。所测得的基因具有以下的序列信息:
(1)序列特征
*长度:330个碱基对
*类型:核酸
*链型:双链
*拓扑结构:线性
(2)分子类型:cDNA
(3)最初来源:奶牛胸腺组织
(4)序列描述:
ATGTCAGACG CGGCCGTGGA CAACAGCTCC GAGATCACCA CCAAGGACTT 50
AAAGGAGAAG AAGGAAGTTG TGGAGGAGGC GGAGAATGGG AGAGAGGCAC 100
CTGCAAATGG GAATGCTAAT GAGGAAAATG GGGAGCAGGA AGCAGACAAC 150
GAGGTAGACG AAGAAGAGGA GGAAGGTGGG GAGGAAGAGG AGGAGGAGGA 200
AGGTGACGGT GAGGAAGAGG ACGGAGATGA AGATGAGGAG GCCGAGGCAG 250
CTACGGGCAA ACGGGCAGCT GAAGATGACG AGGATAACGA TGTGGATACC 300
AAGAAGCAGA AGACTGATAA AGATGAGTAG 330
7.同源检索:利用BLAST软件将分离出的序列与GENEBANK中的序列进行比较。
比较结果:本发明前胸腺素基因序列长度330个碱基,比所公布的其它人和动物的前胸腺素基因缺失3个碱基。与人前胸腺素基因AF348514、BC003510、BC022433、BC051265、J04799和L21693的核苷酸序列差异率分别为9.8%,9.8%,10.5%,9.8%,10.6%,11.2%;与鸡BM486191前胸腺素基因的核苷酸差异率为18.5%,与鼠M20035和NM008972前胸腺素基因的核苷酸差异率为10.1%。
实施例2:表达载体的构建
1.根据实施例1获得的奶牛前胸腺素基因的核苷酸序列,设计引物:
正向引物1’:ATG TCA GAC GCG GCC GTG
反向引物2’:CTC GAG CTA GTC ATC TTT ATC AGT CTT C
2.获得完整的前胸腺素基因
以含奶牛前胸腺素基因的重组质粒为模板,进行聚合酶链反应。
(1)反应体系:
10倍反应缓冲液 5μl
25mM MgCl2 4μl
10mM dNTP 1μl
正向引物1’ 5p mol
反向引物2’ 5p mol
质粒DNA 2μl
Taq DNA聚合酶 0.5μl
无菌水 36.5μl
总体积 50μl
(2)PCR反应条件:94℃3分钟。循环:94℃45秒,51℃50秒,72℃40秒,共计30个循环。72℃延伸5分钟。
3.取600μg酶切的PCR产物与100μg载体连接,连接产物转化大肠杆菌,在含G418的LB平板上筛选抗性转化子。提取质粒后进行酶切和序列测定。将测序正确的菌株甘油保存。
4.大量提取重组载体质粒,纯化后,进行线性化,用LiCl转化法转化酵母菌株,在含G418的YPD平板上筛选抗性转化子。提取质粒后分别以PCR、酶切等方法进一步鉴定抗性转化子。含重组载体的酵母菌株甘油保存。
实施例3:在真核酵母细胞中诱导蛋白表达和表达产物的鉴定
1.在含20ml/L甲醇的BMGY培养基中诱导前胸腺素的表达,每天取细胞培养液1ml,诱导表达7天,样品保存备用。
2.前胸腺素蛋白的分离与纯化
将收集到的细胞培养液9000rpm离心20分钟,收集上清后过Ni2+-chelatingSepharose亲和柱层析纯化蛋白,收集洗脱峰进行活性测定。
3.分子量测定:SDS-PAGE尿素法。样品经SDS聚丙酰氨电泳和银染后,根据标准蛋白确定表达产物的分子量为1.3×104D。
4.蛋白含量测定 以Lowry法进行,用牛血清白蛋白作标准蛋白。
5.纯度鉴定 采用10%和16%两个梯度的PAGE。在垂直电泳槽中,依次加入16%和10%的分离胶聚合,然后再加入浓缩胶,插入样品梳。上样、电泳。电流20mA。电泳完毕后,胶板用50%~0.054%甲醛溶液固定1h,再用0.25%考马斯亮蓝G250染液染2h,以15%甲醇~7.5%乙酸溶液中脱色。
实施例4:生物活性测定
1.淋巴细胞增殖实验(3H-TdR掺入法)
无菌采集小鼠脾脏,在加有无菌石英砂的乳钵中研磨粉碎后,用淋巴细胞分离液分离淋巴细胞,以0.01M PBS pH7.2洗涤两次,离心。沉淀重悬于含10%犊牛血清的1640培养液中。分别于不同时间向96孔培养板中加入脾细胞4×102/孔和不同浓度的前胸腺素,于37℃ CO2孵箱中培养6h,再加入终浓度为5μg/ml的ConA,并设对照组。培养板于37℃,5%CO2条件下培养72h后,每孔加入3H-TdR18.5×10-3GBq继续培养6h,收获细胞于玻璃纤维滤纸上,晾干后,用液闪计数仪检测cpm值。按下式计算增殖率:
增殖率(%)=(实验组cpm值-对照组cpm值)/对照组cpm值×100%
试验结果:
脾细胞和前胸腺素预作用6h时,60-120μg/ml剂量的前胸腺素对淋巴细胞的增殖效果最为明显。高剂量的前胸腺素(>680μg/ml)会有一定的抑制作用。
2.NK细胞活性测定
实验组:小鼠脾淋巴细胞与不同浓度的前胸腺素于37℃作用3h。
对照组:小鼠脾淋巴细胞与培养液于37℃作用3h。
然后用培养液洗涤,沉淀丸重悬于培养液中作为效应细胞。用51Cr释放法测定NK活性。于96孔培养板中分别加入100μl不同浓度的效应细胞和100μl 51Cr标记的YAC-1靶细胞,用培养液代替效应细胞作为自然释放对照。1000rpm离心5min,37℃,5%CO2条件下作用6h,按下式计算细胞毒活性:
细胞毒活性(%)=cpm(实验组-自然释放组)cpm(最大释放组-自然释放组)×100%。
结果表明剂量在10~1000μg/ml范围内的前胸腺素与淋巴细胞作用后可明显增强NK细胞的杀伤作用。
3.IL-1活性检测
实验前3d以TG培养基诱导老龄鼠pMφ,按常规法收集pMφ。以RPM1640培养液配置浓度为2×106/ml的细胞悬液,加至培养板各孔,随后加入LPS及不同浓度的待测药物,作用24h,收获上清,即为含IL-1培养液。以实验小鼠的胸腺细胞为靶细胞,设立三复孔,采用常规3H-TdR掺入法测量IL1活性。设空白对照和阴性对照。
结果表明前胸腺素在LPS的刺激下能明显提高老龄鼠pMφ分泌的IL1的活性。
实施例7:犊牛前胸腺素cDNA的重组应用
将实施例1所获得的犊牛前胸腺素cDNA通过现有的基因工程技术方法,转入酵母菌并得以表达,可用来生产能提高人体免疫力,并具有抗癌作用的胸腺素,用于医药产品的生产制备。
实施例8:胸腺素的临床应用
1.恶性肿瘤
恶性肿瘤在进行化疗和放疗时,对机体免疫功能具有副面影响。李秀清等(1991)将胸腺素用于放疗和化疗肿瘤患者的辅助治疗,经与未使用胸腺素的对照组比较认为:胸腺素能调节和增强肿瘤患者的免疫功能,减轻化疗和放疗的副面作用,提高疗效,延长存活期。动物试验表明胸腺素处理的饿淋巴细胞能明显抑制肺黑色素瘤的转移。郑金娣等(1994)报道胸腺素治疗肺癌的有效率达64%,能增强患者的抵抗力,减轻化疗的反应,该药几乎没有刺激性和毒副反应。
2.病毒性肝炎和肝硬化
胸腺素可以促进IL-2的生成,调节免疫功能,对肝细胞具有直接或间接的保护作用。例涤新等(1989)用胸腺素治疗慢性重症肝炎的研究结果表明治疗组患者的存活率比未治疗组高一倍。高涛等(1997)报道胸腺素具有调节人体细胞免疫功能,能抑制和消除乙肝病毒、治疗乙肝的作用,能使乙肝患者HbeAg的阴转率达到72.27%,乙肝病毒DNA清除率达到54.55%,而且未见任何毒副作用。
3.肾病
胸腺素可增加T细胞绝对数,活化吞噬细胞,可抵消免疫抑制剂治疗的副作用。向毅等(1991)用胸腺素治疗20例肾病患者,发现胸腺素能改善临床症状。
4.扁平疣
芮建新等(1991)用胸腺素治疗扁平疣患者45例,与用左旋咪唑比较,治愈率高21/3倍,有效率高14/6倍。
5.儿童反复呼吸道感染
郑金娟等(1990)应用胸腺素治疗100例呼吸道反复感染患儿,每周1-3次肌注注射,2-3周为一疗程,结果表明总有效率88%,治愈率59%,明显优于对照组。治疗组治疗后免疫功能增前,体重增加,副作用极小。
序列表
<110>山东省科学院生物研究所
<120>奶牛之犊牛前胸腺素基因及其克隆方法与应用
<140>
<141>
<160>2
<170>Patent In3.1
<210>1
<211>330
<212>DNA
<213>奶牛胸腺组织
<400>1
atgtcagacg cggccgtgga caacagctcc gagatcacca ccaaggactt aaaggagaag 60
aaggaagttg tggaggaggc ggagaatggg agagaggcac ctgcaaatgg gaatgctaat 120
gaggaaaatg gggagcagga agcagacaac gaggtagacg aagaagagga ggaaggtggg 180
gaggaagagg aggaggagga aggtgacggt gaggaagagg acggagatga agatgaggag 240
gccgaggcag ctacgggcaa acgggcagct gaagatgacg aggataacga tgtggatacc 300
aagaagcaga agactgataa agatgactag 330
<210>2
<211>109
<212>PRT
<213>奶牛胸腺组织
<400>2
Met Ser Asp Ala Ala Val Asp Asn Ser Ser Glu Ile Thr Thr Lys
1 5 10 15
Asp Leu Lys Glu Lys Lys Glu Val Va1 Glu Glu Ala Glu Asn Gly
20 25 30
Arg Glu Ala Pro Ala Asn Gly Asn Ala Asn Glu Glu Asn Gly Glu
35 40 45
Gln Glu Ala Asp Asn Glu Val Asp Glu Glu Glu Glu Glu Gly Gly
50 55 60
Glu Glu Glu Glu Glu Glu Glu Gly Asp Gly Glu Glu Glu Asp Gly
65 70 75
Asp Glu Asp Glu Glu Ala Glu Ala Ala Thr Gly Lys Arg Ala Ala
80 85 90
Glu Asp Asp Glu Asp Asn Asp Val Asp Thr Lys Lys Gln Lys Thr
95 100 105
Asp Lys Asp Asp 109
Claims (5)
1、奶牛的犊牛前胸腺素基因,其特征在于,序列如下:
ATGTCAGACG CGGCCGTGGA CAACAGCTCC GAGATCACCA CCAAGGACTT 50
AAAGGAGAAG AAGGAAGTTG TGGAGGAGGC GGAGAATGGG AGAGAGGCAC 100
CTGCAAATGG GAATGCTAAT GAGGAAAATG GGGAGCAGGA AGCAGACAAC 150
GAGGTAGACG AAGAAGAGGA GGAAGGTGGG GAGGAAGAGG AGGAGGAGGA 200
AGGTGACGGT GAGGAAGAGG ACGGAGATGA AGATGAGGAG GCCGAGGCAG 250
CTACGGGCAA ACGGGCAGCT GAAGATGACG AGGATAACGA TGTGGATACC 300
AAGAAGCAGA AGACTGATAA AGATGACTAG 330。
2、权利要求1所述的奶牛的犊牛前胸腺素基因的克隆方法,包括如下步骤:
(1)设计特异性引物:
正向引物1:CCA TCT TTG CAT TGT TCC
反向引物2:CTC ATA CAA ACC AAC TCA TTA TAG TAC AGC
(2)从奶牛的犊牛胸腺组织中提取总RNA或mRNA,然后用反转录酶和反向引物2由上述前胸腺素基因的mRNA来产生双链的mRNA/cDNA杂合分子;
(3)用DNA聚合酶、正向引物1和反向引物2在步骤(2)后通过PCR反应产生双链的cDNA分子;
(4)将所得的双链的cDNA分子插入载体内,转化宿主细胞;
(5)宿主细胞增殖后得到含有前胸腺素基因的质粒:
a)提取和确定质粒中前胸腺素基因,
b)将上述基因插入到表达载体内,构建重组表达载体,构建表达载体时获得插入的目的基因PCR反应所用的引物如下:
正向引物1’:ATG TCA GAC GCG GCC GTG
反向引物2’:CTC GAG CTA GTC ATC TTT ATC AGT CTT C
c)上述重组表达载体转化宿主细胞,
d)上述宿主细胞在介质中培养繁殖后,累积前胸腺素蛋白;累积的前胸腺素蛋白被分离和纯化,得到的是犊牛前胸腺素蛋白,该蛋白具有如下的氨基酸序列:
Met Ser Asp Ala Ala Val Asp Asn Ser Ser Glu Ile Thr Thr Lys
1 5 10 15
Asp Leu Lys Glu Lys Lys Glu Val Val Glu Glu Ala Glu Asn Gly
20 25 30
Arg Glu Ala Pro Ala Asn Gly Asn Ala Asn Glu Glu Asn Gly Glu
35 40 45
Gln Glu Ala Asp Asn Glu Val Asp Glu Glu Glu Glu Glu Gly Gly
50 55 60
Glu Glu Glu Glu Glu Glu Glu Gly Asp Gly Glu Glu Glu Asp Gly
65 70 75
Asp Glu Asp Glu Glu Ala Glu Ala Ala Thr Gly Lys Arg Ala Ala
80 85 90
Glu Asp Asp Glu Asp Asn Asp Val Asp Thr Lys Lys Gln Lys Thr
95 100 105
Asp Lys Asp Asp
109。
3、如权利要求2所述的奶牛的犊牛前胸腺素基因的克隆方法,其特征在于,所述步骤(2)的反应组分如下:
反转录酶 1ul
反向引物2 1ul
胸腺素基因的mRNA 13ul
5倍的RT-Buffer 5ul
10mM dNTP 1ul。
4、如权利要求2所述的奶牛的犊牛前胸腺素基因的克隆方法,其特征在于,所述的步骤(3)反应组分和条件如下:
10倍PCR Buffer 5μl
25mM MgCl2 4μl
10mM dNTP 1μl
正向引物 15p mol
反向引物2 5p mol
模板cDNA 2μl
DNA聚合酶 0.5μl
灭菌无离子水 36.5μl
总体积 50μl
PCR反应条件:
94℃4分钟;循环:94℃ 45秒,55℃ 50秒,72℃ 40秒,共30个循环,72℃延伸3分钟。
5、权利要求1所述的奶牛的犊牛前胸腺素基因用于制备胸腺素医药产品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100357369A CN1300315C (zh) | 2004-09-13 | 2004-09-13 | 奶牛之犊牛前胸腺素基因及其克隆方法与应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100357369A CN1300315C (zh) | 2004-09-13 | 2004-09-13 | 奶牛之犊牛前胸腺素基因及其克隆方法与应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1616668A CN1616668A (zh) | 2005-05-18 |
| CN1300315C true CN1300315C (zh) | 2007-02-14 |
Family
ID=34763456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100357369A Expired - Fee Related CN1300315C (zh) | 2004-09-13 | 2004-09-13 | 奶牛之犊牛前胸腺素基因及其克隆方法与应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1300315C (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107759684B (zh) * | 2016-12-09 | 2021-04-20 | 四川好医生攀西药业有限责任公司 | 一种重组美洲大蠊胸腺素蛋白PaTHY1及其表达方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1436847A (zh) * | 2002-02-06 | 2003-08-20 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | 中国人胸腺素α原及其制备方法 |
-
2004
- 2004-09-13 CN CNB2004100357369A patent/CN1300315C/zh not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1436847A (zh) * | 2002-02-06 | 2003-08-20 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | 中国人胸腺素α原及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1616668A (zh) | 2005-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1178956C (zh) | 基于癌抑制基因wt1的产物的癌抗原 | |
| CN101036784A (zh) | 一种乙型肝炎治疗性细胞毒性t细胞表位疫苗及其制备方法 | |
| CN1718243A (zh) | 一类免疫佐剂及其在抗病毒疫苗或药物制备中的应用 | |
| CN1256347C (zh) | 激肽原第五结构域-肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途 | |
| CN1657102A (zh) | 基于表位的SARS-Cov基因疫苗及其构建 | |
| CN1300315C (zh) | 奶牛之犊牛前胸腺素基因及其克隆方法与应用 | |
| CN1171636C (zh) | 一种乙型肝炎dna疫苗 | |
| CN1727362A (zh) | 癌胚抗原阳性肿瘤治疗性疫苗的制备及应用 | |
| CN1765932A (zh) | 一种胸腺素α1和干扰素的融合蛋白 | |
| CN1657626A (zh) | 抗真菌多肽及其制备方法 | |
| CN1948333A (zh) | 一种新的hPEBP4蛋白来源的HLA-A2限制性表位多肽及其应用 | |
| CN1249240C (zh) | 表达载体pBVTB及其构建方法和在HCV疫苗研究中的应用 | |
| CN1195852C (zh) | 可结合生物素的受体分子 | |
| CN1198840C (zh) | 人类乳头瘤病毒11l1-e7重组蛋白及其应用 | |
| CN1425675A (zh) | 棉花Na+/H+反向转运蛋白基因及其克隆方法和应用 | |
| CN1506375A (zh) | 具有广谱抗肿瘤作用的细菌蛋白天青蛋白及其用途和含有其的药物组合物 | |
| CN101054577A (zh) | 抑制Bax基因表达的siRNA和表达载体及其作为乙型病毒性肝炎治疗药物的应用 | |
| CN1803194A (zh) | 用于预防鸡球虫病的免疫调节型dna疫苗 | |
| CN1220701C (zh) | 重组人外周淋巴组织趋化性细胞因子及其制备方法和用途 | |
| CN1322251A (zh) | 一株突变的人乙型肝炎病毒株及其应用 | |
| CN101066993A (zh) | 重组金黄色葡萄球菌肠毒素m及制备和应用 | |
| CN1305898C (zh) | 丙型肝炎病毒被膜蛋白hvr1模拟多肽、其编码基因及用途 | |
| CN1854301A (zh) | 一种表达人血清白蛋白的载体和工程菌 | |
| CN1869064A (zh) | 一种肿瘤抗原蛋白质和肿瘤抗原肽 | |
| CN1876681A (zh) | 抑癌蛋白及其基因和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |